MMV390048 20mg

DRUG2 trials

Sponsors

Medicines for Malaria Venture

Conditions

MalariaMalaria, Falciparum

Phase 1

Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers

CompletedNCT02230579

Medicines for Malaria VentureMalaria

Start: 2014-05-31End: 2015-02-28Updated: 2019-07-17

MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

TerminatedNCT02281344

Medicines for Malaria VentureMalaria, Falciparum

Start: 2014-10-31End: 2014-12-19Updated: 2020-06-09

Related Papers

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers.

2020-03-2450 citations

Plasmodium vivax but Not Plasmodium falciparum Blood-Stage Infection in Humans Is Associated with the Expansion of a CD8+ T Cell Population with Cytotoxic Potential

PLoS neglected tropical diseases2016-12-0829 citations